Skip to content

Total raised

$50K

+$50K this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $50K
ROUNDS
1
INVESTORS
2
FOUNDED
2026
HQ
The Villages, FL
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
N/A

AI overview

Updated

EnduraFAST (operating as Endurazymes) sells an enzyme-screening platform that tells enzyme engineering teams which candidate variants stay properly folded and stable under real-world process stress such as elevated temperature, harsh chemicals, oxygen limitation and time. The platform is built on hsFAST reporter technology developed at Los Alamos National Laboratory: a small, oxygen-independent fluorescent reporter fused to a target enzyme, whose signal tracks proper folding and is lost on misfolding, denaturation or aggregation. Teams screen for durability first and reserve expensive activity testing for the candidates most worth advancing. The company also runs feasibility pilot programs for customers evaluating their own enzyme libraries.

What sets it apart

Adds a stability-first decision layer ahead of activity assays using a fluorescence reporter licensed from Los Alamos National Laboratory, so teams stop spending activity-screening budget on variants that cannot survive industrial conditions.

Funding history

1 round
EquityAug 9, 2026 · $20K min
Form D
+$50K$50K total

Latest SEC filings

via EDGAR · CIK 0002150594
Form D · Aug 9, 2026NewView on EDGAR

Products

1 tracked

EnduraFAST

Protein engineering screening platform

An enzyme screening platform using thermostable hsFAST reporter technology to measure whether enzyme variants remain properly folded and stable after exposure to stress conditions, identifying the strongest candidates early in development.

  • hsFAST fluorescent reporter developed at Los Alamos National Laboratory
  • Fluorescence linked directly to proper protein folding
  • Thermostable readout under elevated-temperature stress
  • Oxygen-independent, so it works in anaerobic and diverse environments